$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Latest from other desks

tml.the modern leap
Health / Public Health

White House Pulls Overton Nomination To Lead FDA

Dr. Heidi Overton's nomination to lead the Food and Drug Administration ended late on Tuesday, hours before the Senate health committee was scheduled to vote. The White House said she did not have the votes, and committee chair Bill Cassidy answered in public that she did and that the administration chose to walk away.

TML Health DeskNov 18, 7:52 AM ET · 3 min read

Edited and fact-checked by Stephen Sprague

FDA Building 1 at the agency's White Oak campus in Silver Spring, Maryland (archive). Photo: FDA.
Summary

The FDA remains under acting leadership while the White House decides on a new nominee, and its mifepristone safety report is due by March.

Tap a passage. React to the part that matters.

The committee room was booked for Wednesday morning, and the nomination did not survive Tuesday night. The White House withdrew Dr. Heidi Overton as its pick to lead the Food and Drug Administration late on Tuesday, a decision a White House official confirmed to news organizations hours before the Senate Health, Education, Labor and Pensions Committee was due to vote on advancing her to the full Senate. There is now no nominee, and the administration has offered no timeline for naming another one.

A senior administration official gave Axios the reason in one sentence. 'FDA nominee Heidi Overton lacks the support on the Hill to move forward with her confirmation,' the official said. Overton is a physician who serves as deputy director of the White House Domestic Policy Council, and the president nominated her on August 19 to replace Dr. Marty Makary, who resigned as commissioner in May. Her confirmation math allowed no defections at all. Republicans hold 12 seats on the committee and Democrats hold 11, no Democrat was expected to back her, and Sens. Susan Collins and Lisa Murkowski had not declared a position hours before the withdrawal.

Bill Cassidy read that math differently, and he said so where the whole Senate could see it. The Louisiana Republican who chairs the committee posted on X late Tuesday that the White House had abandoned a viable confirmation path for Dr. Overton. 'I believe she would have had the votes to pass out of committee and pass the full Senate,' he wrote. In his account, anti-abortion Republicans had asked the White House for commitments on life issues, and 'the Administration withdrew Dr. Overton rather than make such commitments.'

Cassidy's own history with the nominee explains why his post landed so hard. He had called Overton's support for the president's plan to break up combination vaccines, including the measles, mumps and rubella shot, 'almost disqualifying,' and at her September hearing he pressed her on whether she would ever break with the president or with Health Secretary Robert F. Kennedy Jr. on scientific questions. A chairman who had aired doubts that large and still announced she had the votes was telling his own party the withdrawal was a White House choice.

The agency at the center of the fight does not get to pause while Washington looks for a name. The FDA is being led on an acting basis by Kyle Diamantas, an attorney who was the agency's top food official before his elevation in May, and federal rules limit an acting official to about seven months in the job, which puts his clock close to December. The agency is carrying a safety review of the abortion pill mifepristone, requested by the president, with a findings report promised by March, and it is doing that work with about 20 percent fewer employees than it had when the president took office. Overton is the fourth senior health nominee this administration has pulled after Senate resistance, after Dr. David Weldon at the CDC and two surgeon general nominees including Dr. Casey Means, and each withdrawal has left the same agencies under the same acting arrangements for longer.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.